Business Wire

Xinhuanet: Chengdu’s Talent Appeal Spurs the City’s Embrace of the World

Share

“Chengdu is increasingly attracting skilled talent and entrepreneurs to integrate, put down roots, and start businesses in the city. The city continues to become more appealing, which in turn further promotes its international development,” said Xu Wen, head of Southwestern business at PwC’s Chengdu branch.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005704/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Xu Wen, head of Southwestern business at PwC’s Chengdu branch, takes a media interview (Photo: Business Wire)

In the “City of Opportunity 2020” report released by PwC this year, Chengdu ranked 5th in China, only surpassed by Beijing, Shanghai, Guangzhou, and Shenzhen. Xu sees Chengdu’s great advantage as a “new first-tier” city reflected in the city’s appeal to skilled talent. “With China’s economy undergoing transformation and upgrading, innovation capabilities are becoming more and more important. In this context, cultivating developmental advantages is a crucial issue for any city, which means attracting the best talent.”

“Chengdu is very livable and can attract a large pool of skilled workers, as well as their family and friends,” said Xu. “In addition, the city’s development has taken it far beyond traditional modes and culture. Chengdu is now very international and diverse, which has helped attract more global talent, which in turn has further propelled the city’s international development,” he added.

Xu continued, “More importantly, Chengdu adopts a relatively tolerant approach to regulating various industries, striving to maintain new sectors within the scope of legal and business compliance so they can develop healthily. This makes it easier to introduce innovation and continue to attract talent.”

Chengdu now benchmarks itself against the world’s top cities as it strives for a leading position in the network of global cities. As early as 2013, when Xu’s visit to Chengdu coincided with the Global Fortune Forum held there, he was impressed by the level of internationalization.

In Xu’s view, local government support for industry is key to attracting talent. For example, Xu explained, “PwC’s business in Chengdu is located in Wuhou District, which has given us a lot of support and assistance. Since we established in Wuhou, the district government has also become one of our main service partners. This has helped us build trust and relationships with the government, and meanwhile, the government has implemented our advice effectively. This healthy public-private cooperation has benefitted both parties is an incredibly positive development.”

The Chengdu-based development of PwC bears witness to the city’s deepening integration with the outside world. “With the help of PwC’s client network, we have been able to assist local small and medium-sized enterprises to access financial support, as well as new markets, products, and technologies. We strongly recognize how Chengdu provides fertile soil for innovation,” said Xu.

Looking to the future, Xu believes strongly in development prospects for PwC and the city itself: “Chengdu is in a phase of rapid growth, and we are confident PwC can match that while helping promote development, such as supporting the city to train international professionals. Chengdu continues to grow more attractive to talent, and this will spur its international development.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Wei Wang
info@xinhuaeurope.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye